Introduction
Lynch syndrome (LS) is an autosomal dominant disorder caused by inherited defects in the mismatch repair (MMR) system. Individuals with LS have an up to ten times elevated risk of colorectal (CRC) and endometrial cancer compared to the general population 1 . They furthermore have an increased risk of developing tumours of the small bowel, stomach, ovaries, pancreas, ureter and renal pelvis, bladder, biliary tract, brain and sebaceous glands 2, 3 .
The main function of MMR is recognition and repair of replication errors. MSH2 protein can form a heterodimeric complex with MSH6 (hMutSα) or MSH3 (hMutSβ), which can initiate the MMR process by binding to erroneously copied DNA. hMutSα binds single base-base mismatches or single unpaired bases whereas hMutSβ preferentially binds loops of multiple unpaired bases 4, 5 . Mismatch-bound hMutS dimer recruits hMutLα, a dimer of MLH1 and PMS2, which directs further repair.
Most inherited MMR mutations in LS are found in MLH1 and MSH2 (70-80% of cases); mutations in MSH6 and PMS2 account for the remaining 20-30% 6, 7 . When LS is suspected, tumour Background: Lynch syndrome, an autosomal dominant disorder characterized by high colorectal and endometrial cancer risks, is caused by inherited mutations in DNA mismatch repair (MMR) genes. Mutations fully abrogating gene function are unambiguously disease causing. However, missense mutations often have unknown functional implications, hampering genetic counseling. We have applied a novel approach to study three MSH2 unclassified variants (UVs) found in Dutch families with suspected Lynch syndrome. Methods: The three mutations were recreated in the endogenous Msh2 gene in mouse embryonic stem cells by oligo-nucleotide directed gene modification. The effect of the UVs on MMR activity was then tested using a set of functional assays interrogating the main MMR functions. Results : We recreated and functionally tested three MSH2 UVs: MSH2-Y165D (c.493T>G), MSH2-Q690E (c.2068C>G), and MSH2-M813V (c.2437A>G). We observed reduced levels of MSH2-Y165D and MSH2-Q690E but not MSH2-M813V proteins. MSH2-M813V was able to support all MMR functions similar to wild-type MSH2 whereas MSH2-Y165D and MSH2-Q690E showed partial defects. Conclusion: Based on the results from our functional assays we conclude that the MSH2-M813V variant is not disease causing. The MSH2-Y165D and MSH2-Q690E variants affect MMR function and are therefore likely the underlying cause of familial cancer predisposition. Since the MMR defect is partial, these variants may represent low penetrance alleles. material is analysed for microsatellite instability (MSI) and/or expression of MMR proteins by immunehistochemistry (IHC). If a lack of expression is found, the corresponding gene(s) are analysed for mutations. When IHC shows no aberrancies or cannot be done, but the family history is strongly indicative for LS, mutation analysis of all four MMR genes is warranted. The majority of mutations found in LS families are abrogating mutations, such as frameshifts, truncations and deletions, which are unambiguously disease causing. However, also missense mutations are found, whose potential for pathogenicity is much more difficult to predict. These socalled Unclassified Variants (UVs) pose a serious problem to the clinic. As long as it is unclear whether a mutation affects the MMR system, the clinical suspicion of LS cannot be confirmed and no presymptomatic testing is available to identify at-risk family members.
The assess the pathogenicity of UVs, integrative approaches have been proposed to calculate likelihood ratios based on clinical data (segregation analysis, IHC, MSI, loss of heterozygosity) and in silico analysis considering evolutionary conservation and physicochemical differences between amino acids [8] [9] [10] [11] . In addition, functional assays have been developed based on in vitro reconstituted MMR reactions or cellular complementation of MMR deficiency by overexpression of variant MMR proteins, often in distantly related species such as yeast and Escherichia coli. While such approaches can accurately identify fully deleterious mutations, partial MMR defects may remain unnoticed 12 .
We have therefore developed an alternative method to study the functional effects of missense mutations in MSH2 and MSH6 by recreating these variants at the endogenous genes in mouse embryonic stem cells (ESC) using oligonucleotidedirected gene modification 13 . This allows us to study whether and to which extent the variant protein supports the most relevant MMR functions in a highly homologous system 14 (murine MSH2 and MSH6 proteins share 94 and 96% homology with their human counterparts, respectively).
A defect in the MMR system is manifested by length alterations of mononucleotide-or dinucleotide repeat sequences (MSI). Additional functions of the MMR system include the prevention of recombination between homologous but not identical DNA sequences 15, 16 and the cellular response to methylating agents such as 6-thioguanine (6-TG) and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) that add methyl groups to bases in the DNA. MMR prohibits the incorporation of nucleotides opposite methylated guanines during DNA replication, which ultimately leads to double strand breaks [17] [18] [19] . As a result, MMR-proficient cells are sensitive to methylating agents, while MMR-deficient cells are tolerant 15, 20 .
Addressing these functions in ESCs expressing the variant allele provides an accurate and quantitative readout for MMR activity. Here we applied this method to study the functional consequences of three MSH2 missense mutations that have been found in Dutch suspected LS families and found evidence for partial MMR defects.
Results

Selection of UVs
We analysed three unclassified MSH2 variants detected in suspected LS families that are currently being counselled by clinical geneticists in the Netherlands. The main clinical findings are summarised in Table 1 .
The index patient of the first family ( Figure 1A ), referred to the Department of Human Genetics of the Radboud University Medical Center, had colorectal cancer at the age of 51. The tumour showed MSI at mononucleotide but not at dinucleotide markers (Table  1) and normal IHC staining for MLH1 and PMS2 (not shown) and MSH2 and MSH6 (Figure 2A, a) . Lymphocyte DNA sequencing of MSH2, MLH1, MSH6 and PMS2 detected a variant nucleotide in MSH2: c.493T>G resulting in a tyrosine to aspartic acid substitution at position 165 (p.Tyr165Asp), further indicated as Y165D. A brother, also carrier of the UV, developed colon cancer at the age of 42. His tumour showed MSI for all markers tested and the absence of both MSH2 and MSH6. Their father had died of colon cancer at the age of 44 but his MSH2 status is unknown. Of the nine paternal cousins of the index patient, one developed lung cancer at the age of 56, however, their MSH2 status is unknown. No cancer was seen in eight generation-III members, however also their MSH2 status is unknown. The MSH2-Y165D UV was also found in a second unrelated proband who developed CRC at the age of 38. His tumour showed MSI at both types of repeats and absence of MSH2 and MSH6 (Figure 2A, b) . The different MSI and IHC results in the two families raise doubt as to whether the Y165D mutation was responsible for tumour development. In silico analysis gave varying predictions, sorting intolerant from tolerant (SIFT) ,polymorphism phenotyping (Polyphen) and Align-GVGD predicting a polymorphism, the high Grantham score and multi-variate analysis of protein polymorphismsmismatch repair (MAPP-MMR) suggesting pathogenicity (Table 2) . Based on the dissimilarities of tumours in mutation carriers and the ambiguity of the prediction programmes, the UV was classified as a variant of uncertain significance.
The second variant is the MSH2 c.2068C>G mutation, resulting in amino acid substitution p.Gln690Glu (Q690E). This UV was found in lymphocyte DNA of a female who developed colon cancer at the age of 41 and was referred to the Department of Clinical Genetics of the Erasmus Medical Center in Rotterdam ( Figure 1B and Table 1 ). The tumour showed MSI and MSH2 and MSH6 were absent ( Figure 2B ). Next to the MSH2 missense mutation, two single base substitutions, both known polymorphisms, were detected in MSH6: IVS5+14A>T (rs2020911) 21, 22 and a c.268G>A mutation resulting in a glycine to glutamic acid substitution at position 39 (rs1042821) 23, 24 . The patient's brother, who was diagnosed with CRC at the age of 50, also carried the UV. Also his tumour showed MSI and absent MSH2 and MSH6 staining. However, in this family, also a noncarrier developed CRC at young age and some carriers developed a tumour only at high age of which one was microsatellite-stable (MSS) and showed MSH2 and MSH6 staining ( Figure 1B and Table 1 ). Of the four daughters of mutation carrier II-4, one died of heart disease (not shown in the pedigree because their mutation status is unknown). In silico analyses gave varying predictions (Table 2) providing no unambiguous indication for the pathogenicity of this variant. The index patient of the third family was diagnosed at the Netherlands Cancer Institute with carcinoma of the sigmoid at 48 years of age. A hyperplastic polyp was removed 12 years later ( Figure 1C and Table 1 ). The carcinoma was MSS and all four MMR proteins were present ( Figure 2C ). Also her brother developed a carcinoma of the sigmoid at age 49 but no additional clinical data is available. The mother of the patient died at age 79 without cancer. Of her six siblings, four got cancer in their sixties and seventies ( Figure 1C ); according to family history their mother had died of cancer at young age. Mutation analysis in the index patient revealed an A>G change in MSH2 at position 2437, resulting in the amino acid substitution p.MSH2-M813V (M813V) 30 . Most in silico analyses suggested this UV to be neutral but the MAPP-MMR score was indicative for pathogenicity ( Table 2) . Taken together, although the tumour of the index patient showed no signs of MMR deficiency, pathogenicity of the UV could not be excluded.
Functional analysis of UVs
The selected UVs were introduced into the genome of mouse ESCs using oligo targeting 13 (Supplementary Figure 1) and the presence of the mutations was confirmed by sequencing ( Figure 3 We first determined the MSH2, MSH3 and MSH6 protein levels using western blotting to see whether the mutations affected protein stability and dimer formation ( Figure 3 ). The MSH2 levels in Msh2 YD/-and Msh2 QE/-cells were markedly reduced compared with Msh2 +/-and Msh2 MV/-cells, which showed similar levels of MSH2 protein.
The levels of MSH3 and MSH6 provide information about dimer formation since the stability of these proteins depends on the presence of MSH2 31 . Although the MSH3 and MSH6 levels were both reduced in the Msh2 YD/-and Msh2 QE/-cell lines, these proteins were still present in all mutant cell lines, whereas they were virtually absent in Msh2 -/-cells. This indicates that all three MSH2 variants were able to bind and stabilise MSH3 and MSH6.
To study the MMR capacity of the three variant MSH2 proteins, we first determined the mutator phenotype using two assays addressing MSI and mutagenesis at the Hprt gene, respectively. For both assays, three single cells per cell line were expanded to 10 9 cells to allow for approximately 30 population doublings during which mutations could accumulate. The frequency of MSI was then determined by measuring the length of two mononucleotide and two dinucleotide repeats in approximately 30 single cell clones derived from each expanded culture. In Msh2 -/-cells, the levels of mononucleotide and dinucleotide repeat instability were similar, whereas in Msh6 -/-cells mononucleotide repeats were more unstable than dinucleotide repeats ( Figure 4A ). The MSH2-Q690E protein appeared to be fully inactive in the repair of mononucleotide slippage errors since the slippage frequency was as high as in MSH2-deficient and MSH6-deficient cells. The level of dinucleotide repeat instability, however, was only about half of the level found in MSH2-deficient cells indicating some residual activity of MSH2-Q690E. The MSH2-Y165D protein had retained partial repair activity towards mononucleotide slippage errors and almost full activity for dinucleotide slippage events. The level of mononucleotide repeat instability in cells expressing the MSH2-M813V variant was not different from that in wild-type cells and neither was the amount of instability of the dinucleotide repeats. To measure other mutation events, cells from the expanded cultures were exposed to 6-TG at a dose that is lethal to ESCs unless they have obtained an inactivating mutation in the Hprt gene. The MSH2 mutant cell lines generated a lower number of 6-TG-resistant colonies than the MSH2-deficient line, although the mutation frequency varied between the three variant cell lines ( Figure 4A ). The number of 6-TG-resistant colonies was zero (Msh2 MV/-cell line) or comparable to that of Msh2 +/-cells (Msh2 QE/-cell line), suggesting full functionality of these two variants in this assay. Only the Msh2 YD/-cells showed a partial defect in this repair assay with a mutation frequency about half of that of MSH2-deficient cells.
Finally, we studied the ability of the variant MSH2 proteins to mediate the toxicity of methylating DNA damage. Repeated attempts of MMR to repair erroneous incorporation of a thymidine opposite a methylated guanine (MeG) causes formation of lethal double strand breaks. As a result, MMR proficient cells are sensitive to methylating agents such as MNNG and 6-TG, while MMR deficient cells are Figure 4B ). When cells were exposed to 6-TG we again observed that Msh2 MV/-cells were as sensitive as MSH2-proficient cells ( Figure 4C ). In contrast to MNNG however, the Msh2 YD/-and Msh2 QE/-cell lines were partially sensitive to 6-TG, suggesting that these mutant MSH2 proteins had retained some functionality in this assay.
Discussion
In order to support genetic counselling, we have applied our method of MMR gene UV analysis to three MSH2 missense mutations found in suspected LS families that are currently being seen in our clinical genetics centres. Each of these variants is rare: the Y165D variant was detected in two families among 182 families with a proven MMR gene defect seen at the Radboud University Medical Center; the Q690E and M813V variants were detected in only one family and none of the variants was present in the 1000 Genomes database. Segregation analysis and clinical parameters (MSI, IHC) did not allow deciding on the likelihood of pathogenicity of the three variants. Therefore all family members were advised biannual colonoscopy based on the international guidelines for the clinical diagnosis of suspected LS.
In human and mouse MSH2, 92% of the amino acids are identical and the positions of the three variant amino acids studied here are conserved in human, mouse, chicken and fish, but not in fruit fly and yeast. The results of our analyses are summarised in Table 3 . Based on our clinical and experimental data we conclude that the p.MSH2-Tyr165Asp substitution is most likely disease causing, although it may be a reduced penetrance allele. This conclusion contrasts with the PolyPhen, SIFT and Align GVGD predictions, which classified the mutation as benign. However, these prediction models included the protein sequence from the outbred SpragueDawley rat strain, which appears to be the only sequenced mammal that has an aspartic acid at position 165. Recently, the Y165D mutation was found to be completely inactive in an in vitro MMR assay 12 , although our in vivo assays addressing several MMR functions are indicative for some residual activity.
The experimental results obtained for the p.MSH2-Q690E mutation also showed a partial defect, although more severe than the Y165D mutation. This may relate to the location of Q690 in the highly conserved ATPase domain (97% identity between human and mouse 28 ). MSH2-Q690E protein levels were lower than MSH2-Y165D levels, but again MSH3 and MSH6 were visible, indicating proper dimerisation. Mononucleotide instability in Msh2 QE/-ESCs was as high as in Msh2-deficient cells and dinucleotide instability was about half of the level found in Msh2 -/-cells. Surprisingly, the mutation rate in the Hprt assay was very low. Similar to the Msh2 YD/-ESCs, Msh2 QE/-ESCs were resistant to MNNG and partially resistant to 6-TG. Our results correspond with the clinical data. The absence of MSH2 and MSH6 in tumour material is consistent with the very low protein levels in our ESCs. Furthermore, three out of four tumours from the UV carriers showed instability of all five mononucleotide markers tested. When we combine our experimental results with the clinical data, the p.MSH2-Q690E mutation is most likely the pathogenic mutation in this family, although it may be less penetrant than a full knockout allele. Indeed, two carriers of the UV did not develop an MSI tumour: whereas one carrier (II-2) did not develop cancer at all, the adenocarcinoma that developed in family member II-6 was MSS and showed staining for all four MMR proteins and was therefore likely sporadic. However, it is also possible that development of MSI tumours in these individuals was hampered by specific modifier genes 33, 34 . Also the two MSH6 single base substitutions that were found in the lymphocyte DNA from the index patient, IVS5+14A>T and c.268G>A resulting in a glycine to glutamic acid substitution at position 39 could play a role. The first is a known polymorphism for which no correlation with CRC risk has been found 22 . Instead, homozygosity for the G39E substitution has been associated with a modestly increased risk for rectal cancer 35 , and a small increase in colon cancer incidence has been reported among male carriers of this mutation (odds ratio 1.27) 36 . It is therefore possible that the MSH6-G39E variant affects tumour predisposition in carriers of the MSH2-Q690E mutation. However, to exert such an effect, the two mutations must reside on the same chromosome since MSH2 and MSH6 are closely located on chromosome 2: if the mutations were on different chromosomes, an LOH event eliminating the wild-type MSH2 allele would also eliminate the mutant MSH6 allele. Therefore, variable inheritance of the MSH6-G39E mutation unlikely explains the variable tumour incidence and characteristics in carriers of the MSH2-Q690E mutation.
Although family history suggested a strong predisposition for colorectal cancer, the p.MSH2-M813V substitution is unlikely to be the cause. Consistent with microsatellite stability and the presence of all four MMR proteins in the tumour from the index patient, we saw no reduction in protein level and no functional MMR defects in our mouse Msh2 MV/-ESCs. Of note, the mutation underlying the human M813V variant was analysed in SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer and Human Splice Finder, but none of them indicated an effect on splicing. We therefore classify this variant as non-pathogenic.
In summary, we have recreated three MSH2 UVs found in Dutch families and analysed their effect on different MMR functions. By targeting the highly homologous mouse MMR genes and subsequent inactivation of the wildtype allele in ESCs, we closely mimicked the human situation. Combined with the clinical data, our experimental results provide strong indications for the pathogenicity of two of these UVs. We have previously shown that in all our assays a proven deleterious mutant, MSH2-P622L, behaved indistinguishable from a full MSH2 knockout allele 14 . Therefore, the intermediate phenotypes of MSH2-Y165D and MSH2-Q690E in our assays are real manifestations of partial MMR defects. Attenuated MMR activity may remain unnoticed in in vitro MMR assays using purified proteins or cellular overexpression systems. Although it is unlikely that the mutations we have examined affect gene regulation or splicing, it is unfortunate that we have not been able to formally exclude this possibility by analysis of cDNA prepared from tumour or normal tissue.
We believe our approach is a valuable alternative to existing functional assays and will facilitate UV classification and subsequent counseling. However, we realize translating laboratory data to clinical practice is challenging. Recently, classification systems have been proposed that predominantly rely on clinical information. As this information is often insufficient or inconsistent, Plon et al. have proposed five classes of variants based on the likelihood of pathogenicity 37 . The authors proposed that proper interpretation of all aspects used to classify variant alleles requires a panel of experts covering the range of expertise required. While this classification system will certainly provide guidance to clinical geneticists, we believe that state of the art patient care dictates full exploitation of scientific knowledge. The MMR system has been extensively studied for decades in bacteria, yeast and higher eukaryotes. This has generated a wealth of knowledge about the function and functioning of MMR genes and yielded ample protocols for experimentally testing the MMR capacity of individual MMR gene variants. The inclusion of functional assays in any classification system for MMR gene variants is therefore highly desirable, a viewpoint also advocated by Rasmussen et al. 38, 39 . With this report we intend to contribute to this discussion and to lower the barrier to clinical implementation of functional tests. Extending the panel of experts proposed by Plon et al. 37 by a molecular biologist ensures full advantage to be taken from the outcome of functional assays.
Materials and Methods
Molecular analyses of human tumours
For MSI analysis, genomic DNA was isolated from formalin-fixed paraffin-embedded tissue and normal tissue, essentially as described by Hoogerbrugge et al. 40 . Microsatellite markers BAT40, BAT26, D1S158, D2S123, BAT25, D5S346, D9S63, D17S250 and D18S58 were used in various combinations. According to international guidelines, a tumour was considered MSI-high when at least two out of five markers showed length alterations. IHC was performed on formalin-fixed, paraffin-embedded tumour and normal tissues, using antibodies against MLH1 (Pharmingen code: 51-1327gr and Novocastra/Leica clone ES05), PMS2 (Pharmingen code: 556415 and Epitomics clone EPR3947), MSH2 (Oncogene Research Products code: NA26 and Pharmingen clone G219-1129) and MSH6 (Transduction Laboratories code: G70220 and Pharmingen clone 44/MSH6).
Mutation analyses in humans
DNA extracted from peripheral blood lymphocytes was analysed for MSH2, MSH6, MLH1 and PMS2 mutations by a capillary sequence analysis and multiplex ligation-dependent probe amplification (MLPA, MRC-Holland kit P003-B1). IHC, MSI analyses and sequencing of MMR genes were performed in the context of a referral to genetic counselling, for diagnostic purposes and after consent had been obtained.
Generation of codon substitutions in Msh2
The oligonucleotide-directed gene modification ('oligo targeting') procedure was carried out in wild-type ESCs, essentially as described 13 . Briefly, we transfected ESCs with a singlestranded DNA oligonucleotide (Supplementary Figure 1) after establishing transient down regulation of MLH1. Transfected cells were expanded and plated on 96-well plates at 5000 cells/well. Mutation-specific PCR was used to identify pools containing mutated cells as described 14 . A positive pool was subcloned using limiting dilution in subsequent pools of 1000, 100 and 1 cell/well. Once a clonal cell line was established, cDNA was made using an oligo dT primer. We then amplified a cDNA fragment containing the modified codon by PCR. The resulting PCR product was cloned into the pGEM-T Easy vector (Promega) and sequenced to verify the presence of the mutation using vector primers T7 and SP6. Primer sequences are available upon request.'
Inactivation of the wild-type allele
For inactivation of the wild-type allele in Msh2 YD/+ and Msh2 MV/+ ESCs, we used a targeting vector derived from Claij and Te Riele 41 , in which exon 12 was removed by deleting a SnaB1-Swa1 fragment (Supplementary Figures 2 and 4) . In Msh2 QE/+ cells, the wild-type allele was inactivated using a targeting vector in which exon 12 was disrupted by a hygromycin resistance marker (Supplementary Figure 3) 15 . Details of the procedure are given in the legends to Supplementary Figures 2, 3 and 4 .
Western blot analysis
Cells were lysed in a buffer containing 150 mM NaCl, 50 mM Hepes pH 7.5, 5 mM EDTA, 0.1% NP-40, 5 mM NaF, 0.5 mM vanadate, 20 mM β-glycerolphosphate and 1 tablet complete protease inhibitor cocktail (Roche) per 50 ml. Protein concentrations were measured using the Pierce BCA protein assay kit (Thermo scientific) and equal amounts of each sample were separated by 3-8% Tris-Acetate gels (NuPAGE) using the NuPAGE electrophoresis system and transferred to nitrocellulose membrane. We used rabbit polyclonal antibodies as primary antibodies to detect MSH2 (1:500) and MSH6 (1:500), and mouse monoclonal antibodies to detect MSH3 (1:50) 42 and γ-Tubilin (GTU-88, SigmaAldrich). Peroxidase-conjugated goat anti-rabbit IgG and goat anti-mouse IgG (BioSource International) were used as a secondary antibody. Signals were visualised with enhanced chemiluminescence.'
Hprt mutation assay
Single cells of the mutant cell lines Msh2 YD/-, Msh2 QE/-and Msh2 MV/-, and the control cell lines Msh2 +/+ , Msh2 +/-and Msh2 -/-were expanded to 10 9 cells. Each expanded clone was plated onto three 150 mm gelatine-coated tissue culture plates at 1.5 x 10 6 cells/plate. The next day, 6-TG was added at a final concentration of 10 μg/ml. After 10 days, the resistant colonies were counted.
MSI assay
A minimum of three single-cell clones of each mutant and control cell line were expanded to 10 9 cells. Of each of the expanded cultures we generated 32 subclones and isolated genomic DNA. The length of two dinucleotide microsatellite markers (D7Mit17 and D14Mit15) as well as two mononucleotide markers (mBAT-26 and mBAT37) was analysed by PCR analysis.
Sensitivity to MNNG and 6-TG
The mutant cell lines, Msh2 YD/-, Msh2 QE/-and Msh2 MV and the control cell lines, Msh2 +/+ , Msh2 +/-and Msh2 -/-were plated onto irradiated mouse embryonic fibroblast feeder layers at a density of 500 cells/1.8 cm 2 . The next day we treated the cells for 1 hour with 0-40 μM MNNG or 6-TG and after 4 days we counted the number of surviving colonies. In the case of MNNG exposure, cells were cultured in the presence of 40 μM O 6 -benzylguanine, starting from 1 hour prior to MNNG exposure until counting of the colonies. O 6 -benzylguanine inhibits the removal of methyl groups from the O 6 position of guanine by endogenous O 6 -methylguanine-methyltransferase activity. 
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